Study of Octanorm Subcutaneous IG in Patients With PID



Status:Active, not recruiting
Conditions:Infectious Disease, HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:2 - 75
Updated:2/14/2019
Start Date:March 2014
End Date:December 2019

Use our guide to learn which trials are right for you!

Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases

This is an open-label phase III study with a 12-week wash-in/wash-out period followed by a
12-month efficacy period. The main goals of the study are to assess the efficacy of octanorm
in preventing serious bacterial infections (SBI) compared with historical control data and to
evaluate the pharmacokinetic (PK) characteristics of octanorm.


Inclusion Criteria:

1. Age of at least 2 years up to and including 75 years.

2. Confirmed diagnosis of PI as defined by the ESID and PAGID and requiring
immunoglobulin replacement therapy due to hypogammaglobulinaemia or
agammaglobulinaemia. The exact type of PI should be recorded.

3. Patients with at least 6 infusions on regular treatment with any IVIG, there of a
minimum of the last 2 months on the same product prior to entering the study. Constant
IVIG dose between 200 and 800 mg/kg body weight (±20% of the mean dose for the last 6
infusions).

4. Availability of the IgG trough levels of 2 previous IVIG infusions before enrollment,
and maintenance of greater than or equal to 5.0 g/L in the trough levels of these 2
previous infusions.

5. Negative result on a pregnancy test (HCG-based assay in urine) for women of
childbearing potential and use of a reliable method of contraception for the duration
of the study.

6. For adult patients: freely given written informed consent. For minor patients: freely
given written informed consent from parents/legal guardians and written informed
assent from the child/adolescent in accordance with the applicable regulatory
requirements.

7. Willingness to comply with all aspects of the protocol, including blood sampling, for
the duration of the study.

Exclusion Criteria:

1. Acute infection requiring intravenous antibiotic treatment within 2 weeks prior to and
during the screening period.

2. Known history of adverse reactions to IgA in other products.

3. Patients with body mass index ≥40 kg/m2.

4. Exposure to blood or any blood product or plasma derivatives, other than IVIG
treatment for PID, within the past 3 months prior to the first infusion of octanorm.

5. Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived
products, or any component of the investigational product (such as Polysorbate 80).

6. Requirement of any routine premedication for IgG administration.

7. History of malignancies of lymphoid cells and immunodeficiency with lymphoma.

8. Severe liver function impairment (ALAT 3 times above upper limit of normal).

9. Known protein-losing enteropathies or proteinuria.

10. Presence of renal function impairment (creatinine greater than 120 uM/L), or
creatinine greater than 1.35 mg/dL), or predisposition for acute renal failure (e.g.,
any degree of pre-existing renal insufficiency or routine treatment with known
nephritic drugs).

11. Treatment with oral or parenteral steroids for greater than or equal to 30 days or
when given intermittently or as bolus at daily doses greater than or equal to 0.15
mg/kg.

12. Treatment with immunosuppressive or immunomodulatory drugs.

13. Live viral vaccination (such as measles, rubella, mumps and varicella) within the last
2 months prior to first infusion of octanorm.

14. Treatment with any investigational medicinal product within 3 months prior to first
infusion of octanorm.

15. Presence of any condition, that is likely to interfere with the evaluation of study
medication or satisfactory conduct of the trial.

16. Known or suspected to abuse alcohol, drugs, psychotropic agents or other chemicals
within the past 12 months prior to first infusion of octanorm.

17. Known or suspected HIV, HCV, or HBV infection.

18. Pregnant or nursing women.

19. Planned pregnancy during the course of the study.
We found this trial at
8
sites
Frisco, Texas 75034
?
mi
from
Frisco, TX
Click here to add this to my saved trials
Birmingham, Alabama 35233
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Centennial, Colorado 80112
?
mi
from
Centennial, CO
Click here to add this to my saved trials
?
mi
from
Edmonton,
Click here to add this to my saved trials
Irvine, California 92697
?
mi
from
Irvine, CA
Click here to add this to my saved trials
Omaha, Nebraska 68124
?
mi
from
Omaha, NE
Click here to add this to my saved trials
3232 Duke Street
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Toledo, Ohio 43617
?
mi
from
Toledo, OH
Click here to add this to my saved trials